Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya.

Limited objective data are available for the prevalence of peripheral neuropathy (PN) among antiretroviral (ART)-treated human immunodeficiency virus (HIV)-infected patients in resource-limited settings A validated neuropathy-screening tool was integrated into routine ART visits at an HIV clinic in Mombasa, Kenya. Diagnosis of PN required at least one symptom and either abnormal vibratory sensation or deep tendon reflex bilaterally. Among 102 consecutively screened patients, 63% were women, 62% were receiving ART for <= 1 year, and 86% were receiving a stavudine (D4T)-based regimen Thirty-seven (36%) had PN Univariate analysis showed that current D4T use was protective against PN (P = 0 03) and older age was a marginal risk factor (P = 0 05) Multivariate analysis showed that older age was a risk factor for neuropathy (P = 0 04) Peripheral neuropathy was common. particularly among older HIV-infected adults in Kenya The protective association with current D4T use likely represents survivor effect bias Longitudinal studies using this screen will help further characterize PN in resource-limited settings